Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study

NCT04676412 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Lenvatinib
DRUG: Placebo for lenvatinib

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]